Estrogen Deficiency Symptom Management in Breast Cancer Survivors in the Changing Context of Menopausal Hormone Therapy

Seminars in Oncology

Volumn 30, Issue 6, 2003, Pages 776-788

  Chlebowski, Rowan T ^a   Kim, Jung A ^b   Col, Nananda F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BELLERGAL; BUSERELIN; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; FLUOROURACIL; FLUOXETINE; FULVESTRANT; GABAPENTIN; GESTAGEN; GOSERELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; VENLAFAXINE;

AMENORRHEA; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; COGNITIVE DEFECT; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG ABSORPTION; DRUG SAFETY; ESTROGEN DEFICIENCY; FOOD AND DRUG ADMINISTRATION; FRACTURE; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; VASOMOTOR DISORDER;

EID: 0346363756     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.021     Document Type: Article

References (89)

1. Pritchard KI: Adjuvant therapy for premenopausal women with breast cancer: Is it time for another paradigm shift? J Clin Oncol 20:4611-4614, 2002
2. Henderson IC: A rose is no longer a rose. J Clin Oncol 20:3365-3368, 2002
3. Goss P, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894, 2001
4. Writing Group for the Women's Health Initiative: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 288:321-333, 2002
5. Beral V, Banks E, Reeves G: Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 360:942-944, 2002
6. Minton SE, Munster PN: Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9:466-472, 2002
7. Jemal A, Murray T, Samuels A, et al: Cancer statistics 2003. CA Cancer J Clin 53:5-26, 2003
8. Kroman H, Jensen MB, Wohlfahrt J, et al: Factors influencing the effect of age on prognosis in breast cancers: Population based study. Commentary: much still to learn about relations between tumor biology, prognosis, and treatment outcome in early breast cancer. Br Med J 320:474-479, 2000
9. Winer EP, Hudis L, Burstein HJ, et al: American Society of Clinical Oncology Technology Assessment: The use of aromatase inhibitors as adjuvant therapy for women with hormone receptor positive breast cancer. J Clin Oncol 20:3119-3131, 2002
10. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
11. Goodwin PJ, Ennis M, Pritchard KI, et al: Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17:2365-2370, 1999
12. Nabholtz JM, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BICRG 001 study. Proc Am Soc Clin Oncol 21:141, 2002 (abstr)
13. Goldhirsch A, Gelber RD, Yothers G, et al: Adjuvant therapy for very young women with breast cancer: Need for tailored treatments. J Natl Cancer Inst 30:44-51, 2001
14. Klijn JGM, Beex LVAM, Mauriac L, et al: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 92:903-911, 2000
15. Houghton J, Baum M, Rutqvist L, et al: The ZIPP trial of adjuvant zoladex in premenopausal patients with early breast cancer: An update at five years. Proc Am Soc Clin Oncol 19:359, 2000 (abstr)
16. Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635, 2002
17. Jakesz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockage in premenopausal patients with hormone-responsive breast cancer. J Clin Oncol 20:4611-4614, 2002
18. Davidson NE, O'Neill A, Vukov CK, et al: Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proc Am Soc Clin Oncol 15, 2003 (abstr)
19. Chlebowski RT: Reducing the risk of breast cancer. N Engl J Med 343:191-198, 2000
20. Chlebowski RT, Col N, Winer EP, et al: American Society of Clinical Oncology Technology Assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20:3328-3343, 2002
21. Lorrain JM, Ploffe L, Ravnikar V, et al: Comprehensive Management of Menopause. Springer-Verlag, New York, NY, pp 5-24, 1994
22. Speroff L, Glass RH, Kare NG: Clinical Gynecologic Endocrinology and Infertility (ed 6). Philadelphia, PA, Lippincott, William & Wilkins, 1999, pp 282-297
23. Geisler J, Haynes B, Anker G, et al: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757, 2002
24. Yasui T, Uemura H, Tezuka M, et al: Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res 56:38-44, 2001
25. Henderson BE, Ross R, Bernstein L: Estrogen as a cause of human cancer: The Richard and Hilda Rosenthal Foundation Award lecture. Cancer Res 48:246-253, 1988
26. Cauley JA, Lucas FL, Kuller LH, et al: Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer. Ann Intern Med 130:270-277, 1999
27. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059, 1997
28. Ross RK, Paganini-Hill A, Wan PC, et al: Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328-332, 2000
29. Chlebowski RT, Hendrix SL, Langer RD, et al: Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 289:3243-3253, 2003
30. Marsden J: Hormone-replacement therapy and breast cancer. Lancet Oncol 3:303-311, 2002
31. Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427, 2003
32. Pritchard KI, Khan H, Levine M: Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. Can Med Assoc J 166:1017-1022, 2002
33. Chlebowski RT, McTiernan A: Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol 17:130-142, 2000
34. Hulley S, Furberg C, Barrett-Connor E, et al: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II): Non cardiovascular disease outcomes during 6-8 years of hormone therapy. JAMA 288:872-881, 2002
35. US Preventive Services Task Force: Recommendation and rationale. Hormone replacement therapy for primary prevention of chronic conditions. http://www.ahcpr.gov/clinic/3rduspstf/hrt/httrr.htm
36. Shumaker SA, Legault C, Rapp SR, et al: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA 289:2651-2662, 2003
37. Ursic-Vrscaj M, Bebar S: A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 25:146-151, 1999
38. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al: Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively. J Clin Oncol 17:1482-1487, 1999
39. O'Meara ES, Rossing MA, Daling JR, et al: Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93:754-762, 2001
40. Beckmann MW, Jap D, Djahansouzi S, et al: Hormone replacement therapy after treatment of breast cancer: Effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 60:199-206, 2001
41. Durna EM, Wren BG, Heller GZ, et al: Hormone replacement therapy after a diagnosis of breast cancer: Cancer recurrence and mortality. Med J Aust 177:340-341, 2002
42. Col NF, Hirota LK, Orr RK, et al: Hormone replacement therapy after breast cancer: A systematic review and quantitative assessment of risk. J Clin Oncol 19:2357-2363, 2001
43. Dew JE, Wren BG, Eden JA: Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: A cohort study. Climacteric 5:151-155, 2002
44. Stein KD, Jacobsen PB, Hann DM, et al: Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage 19:436-445, 2000
45. Ganz PA, Desmond KA, Belin TR, et al: Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17:2371-2380, 1999
46. Stearns V, Ullmer L, Lopez JF, et al: Hot flushes. Lancet 360:1851-1861, 2002
47. Shanafelt TD, Barton DL, Adjel AA, et al: Pathophysiology and treatment of hot flashes. Mayo Clin Proc 77:1207-1218, 2002
48. Fitzpatrick LA, Santen RJ: Hot flashes: The old and new, what is really true? Mayo Clin Proc 77:1155-1158, 2002
49. Jacolsen PB, Weitzner MA: Evaluation and management of hot flashes in cancer patients, in Berger AM, Postenay RK, Weissman DE (eds): Principles and Practice of Supportive Oncology. New York, NY, Lippincott Williams & Wilkins, 2002, pp 1-13
50. Carpenter JS, Johnson D, Wagner L, et al: Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 29:E16-E25, 2002
51. Sloan JA, Loprinzi CL, Novotny PJ, et al: Methodologic lessons learned from hot flash studies. J Clin Oncol 19:4280-4290, 2001
52. MacLennan A, Lester S, Moore V: Oral oestrogen replacement therapy versus placebo for hot flashes. Cochrane Database Syst Rev CD002978, 2001
53. Utian WH, Shoupe D, Bachmann G, et al: Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 75:1065-1079, 2001
54. Bertelli G, Venturini M, Del Mastro L, et al: Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: A randomized study. Ann Oncol 13:883-888, 2002
55. Loprinzi CL, Michalak JC, Quella SK, et al: Megestrol acetate for the prevention of hot flashes. N Engl J Med 331:347-352, 1994
56. Leonetti HB, Longo S, Anasti JN: Transdermal progesterone cream for vasomotor symptoms and menopausal bone loss. Obstet Gynecol 94:225-228, 1999
57. Cobau CD, Declercq K, Neuberg D, et al: A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer: A study of the Eastern Cooperative Oncology Group. Cancer 77:483-489, 1991
58. Segahoff A, Gordon D, Carabasi RE, et al: Hormonal therapy in cancer of the breast: VII. Effect of conjugated estrogens (equine) on clinical course and hormonal excretion. Cancer 7:758-763, 1954
59. Smith IE, Ford HT, Gazet JC, et al: Premarin in the management of metastastic breast carcinoma in postmenopausal patients. Clin Oncol 5:159-162, 1979
60. Henriksson L, Stjernquist M, Boquist L, et al: A one-year multicenter of efficacy and safety of continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 174:85-92, 1996
61. Naessen T, Rodriguez-Macias K: Serum lipid profile improved by ultra-low doses of 17beta-estradiol in elderly women. J Clin Endocrinol Metab 86:2757-2762, 2001
62. Law M, Loprinzi CL, Kugler J, et al: Double-blind crossover trial of Replens versus KY jelly for treating vaginal dryness and dysparunia in breast cancer survivors. Proc Am Soc Clin Oncol 15:241, 1996 (abstr)
63. Goldberg RM, Loprinzi CL, O'Fallon JR, et al: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 12:155-158, 1994
64. Pandya KJ, Raubertas RF, Flynn PJ, et al: Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 132:788-793, 2000
65. Vercellini P, Vendola N, Colombo A, et al: Veralipride for hot flashes during gonadotropin releasing hormone agonist treatment. Gynecol Obstet Invest 34:102-104, 1992
66. Wesel S, Bourguignon RP, Bosuma WB: Veralipride versus conjugated oestrogens: A double-blind study in the management of menopausal hot flashes. Curr Med Res Opin 8:696-700, 1984
67. Lebherz TB, French L: Nonhormonal treatment of the menopausal syndrome: A double-blind evaluation of an autonomic system stabilizer. Obstet Gynecol 33:795-799, 1969
68. Kronenberg F, Fugh-Berman A: Complementary and alternative medicine for menopausal symptoms: A review of randomized, controlled trials. Ann Intern Med 137:805-813, 2002
69. Chenoy R, Hussains S, Tayob Y, et al: Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ 308:501-503, 1994
70. Lieberman S: A review of the effectiveness of Cimifuga racemosa (black cohosh) for the symptoms of menopause. J Women Health Initiat 7:525-529, 1998
71. Pepping J: "Black cohosh": Cimifuga racemosa. Am J Health Systems Pharm 56:1400-1402, 1999
72. Jacobson JS, Troxel AB, Evans J, et al: Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 19:2739-2745, 2001
73. Quella SK, Loprinzi CL, Barton DL, et al: Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 18:1068-1074, 2000
74. Van Patten CL, Olivotto IA, Chambers GK, et al: Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: A randomized, controlled clinical trial. J Clin Oncol 20:1449-1455, 2002
75. Hirata JD, Swiersz LM, Zell D, et al: Does dong quai have estrogenic effects in postmenopausal women?: A double-blind, placebo-controlled trial. Fertil Steril 68:981-986, 1997
76. Barton DL, Loprinzi CL, Quella SK, et al: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16:495-500, 1998
77. Loprinzi CL, Kugler JW, Sloan JA, et al: Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet 356:2059-2063, 2000
78. Loprinzi CL, Sloan JA, Perez EA, et al: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20:1578-1583, 2002
79. Barton DL, Loprinzi CL, Sloan SR, et al: Pilot evaluations of newer antidepressants for hot flashes. Proc Am Soc Clin Oncol 21:1463, 2002 (abstr)
80. Clayton AH, Pradko JF, Croft HA, et al: Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63:357-366, 2002
81. Loprinzi CL, Barton DL, Sloan JA, et al: Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 77:1159-1163, 2002
82. Ivarsson T, Spetz AC, Aammar M: Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas 29:139-146, 1998
83. Ganz PA, Greendale GA, Petersen L, et al: Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Natl Cancer Inst 92:1054-1064, 2000
84. Bydder SA, Spry NA: Treatment for hot flashes in women receiving tamoxifen. Med J Aust 177:266-268, 2002
85. Bond B, Hicota L, Fortium J, et al: Women like me: Reflection on health and hormones from women treated for breast cancer. J Psychosoc Oncol 20:39-56, 2002
86. Malenka DJ, Baron JA, Johansen S, et al: The framing effect of relative and absolute risk. JGIM 8:543-548, 1993
87. Forrow L, Taylor WC, Arnold RM: Absolutely relative: How research results are summarized can affect treatment decisions. Am J Med 92:121-124, 1992
88. Bucher HC, Weinbacher M, Gyr K: Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 309:761-764, 1994
89. Hux JE, Naylor CD: Communicating the benefits of chronic preventive therapy: Does the format of efficacy data determine patients' acceptance of treatment? Med Decis Mak 15:152-157, 1995